2018
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology 2018, 20: vi10-vi10. PMCID: PMC6216157, DOI: 10.1093/neuonc/noy148.034.Peer-Reviewed Original ResearchToll-like receptorsMedian survivalDendritic cellsDC vaccinesGrade III or IV gliomaTumor lysate-pulsed DCGlioblastoma multiformePoly ICLCAutologous tumor lysateDC vaccine treatmentLysate-pulsed DCMGMT methylated tumorsMGMT unmethylated tumorsTLR-7 agonistPeripheral blood mononuclear cellsGrade III tumorsTLR-3 agonistIncreased overall survivalGrade IV tumorsBlood mononuclear cellsModulate immune responsesIII tumorsIV tumorsMethylated tumorsOverall survival
2017
Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme
Qin Y, Takahashi M, Sheets K, Soto H, Tsui J, Pelargos P, Antonios J, Kasahara N, Yang I, Prins R, Braun J, Gordon L, Wadehra M. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme. Journal Of Neuro-Oncology 2017, 134: 29-40. PMID: 28597184, PMCID: PMC5695892, DOI: 10.1007/s11060-017-2507-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigens, CD34Cell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticGlioblastomaGreen Fluorescent ProteinsHuman Umbilical Vein Endothelial CellsHumansImmunoglobulin GMembrane GlycoproteinsMiceMice, NudeMicroarray AnalysisNeovascularization, PathologicRNA, Small InterferingTransfectionVascular Endothelial Growth Factor AXenograft Model Antitumor AssaysConceptsExpression of epithelial membrane protein-2Anti-angiogenic therapyEpithelial membrane protein-2Glioblastoma multiformeSurvival benefitAnti-vascular endothelial growth factor AProgression-free survival benefitReduction of tumor loadDecreased tumor vasculatureRecurrent glioblastoma multiformeVEGF-A levelsEndothelial growth factor AAbnormal blood vesselsProtein 2Malignant brain tumorsAggressive malignant brain tumorGrowth factor AHuman glioblastoma multiformePotential therapeutic effectsTumor loadTumor expressionPro-angiogenic effectsTumor vasculatureClinical prognosisVEGF-A
2015
IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS
Sedighim S, Hsu M, Antonios J, Emerson R, Yusko E, Sanders C, Davidson T, Liau L, Prins R. IMCT-11NEXT GENERATION T CELL RECEPTOR SEQUENCING CAN IDENTIFY, QUANTIFY, AND TRACK TUMOR-SPECIFIC T CELL POPULATIONS BEFORE AND AFTER DENDRITIC CELL VACCINATION IN GLIOBLASTOMA MULTIFORME PATIENTS. Neuro-Oncology 2015, 17: v109-v110. PMCID: PMC4638907, DOI: 10.1093/neuonc/nov218.11.Peer-Reviewed Original Research